Skip to main content

$0.180 -0.005 (-2.70%)

High

$0.20

Low

$0.18

Trades

151

Turnover

$593,932

Volume

3,225,766
30 June 2023 at 4:10pm
Register to track IPD and receive email alerts.
Subject
IPD Ann: Notice under Section 708A(5)(e) of the Corporations Act

IPD Ann: Appendix 2A

IPD Ann: Option Exercise and Preliminary Q3 FY21 Cashflow Results

IPD Ann: Notice of Exercise of Options

IPD Ann: ImpediMed Achieves Milestone 200,000 SOZO Patient Tests

IPD Ann: ImpediMed COVID19 US CARES Act Loan Forgiven

IPD Ann: Appendix 4D - Half-Year Results Ended 31 December 2020

IPD Ann: American College of Cardiology Accepts SOZO HF Abstract

IPD Ann: Appendix 4C - Quarter ended 31 December 2020

IPD Ann: ImpediMed Quarterly Results and Investor Conference Call

IPD Ann: Change in substantial holding

IPD Ann: Change in substantial holding

IPD Ann: PREVENT Trial Finishes, Final Patient Completes Follow-up

IPD Ann: Ceasing to be a substantial holder from AEF

IPD Ann: Appendix 2A

IPD Ann: Option Exercise and Preliminary Quarterly Cash Flow Results

IPD Ann: Change of Director's Interest Notice - Donald Williams

IPD Ann: Change of Director's Interest Notice - Amit Patel

IPD Ann: Change of Director's Interest Notice - Scott Ward

IPD Ann: Change of Director's Interest Notice - Dr Robert Graham

IPD Ann: Change of Director's Interest Notice - Judith Downes

IPD Ann: Change of Director's Interest Notice - Richard Carreon

IPD Ann: Change of Director's Interest Notice - David Anderson

IPD Ann: Notice under Section 708A(5)(e) of the Corporations Act

IPD Ann: Appendix 2A

IPD Ann: Appendix 3G

IPD Ann: ImpediMed Secures HITRUST Certification

IPD Ann: Notice of Exercise of Options

IPD Ann: Meta-Analysis-BIS L-Dex Statistically Significant Reduction

IPD Ann: Notification of Investor Conference Call - Meta-Analysis

IPD Ann: ImpediMed Secures First Commercial Heart Failure Sales

IPD Ann: Revised Appendix 3Y

IPD Ann: Change of Director's Interest Notice - Richard Carreon

IPD Ann: Notice under Section 708A(5)(e) of the Corporations Act

IPD Ann: Appendix 2A

IPD Ann: NSW Health Further Expands Lymphoedema Prevention Program

IPD Ann: Change in substantial holding

IPD Ann: Change of Director's Interest Notice - Richard Carreon

IPD Ann: AstraZeneca Selects SOZO for Second Large Renal Trial

IPD Ann: Notice under Section 708A(5)(e) of the Corporations Act

IPD Ann: Appendix 2A

IPD Ann: Appendix 3G

IPD Ann: Landmark Radiation Manuscript Supports L-Dex Use

IPD Ann: Results of Meeting

IPD Ann: Investor Presentation

IPD Ann: IPD 2020 AGM - Chairman's Address

IPD Ann: Appendix 4C - Quarter ended 30 September 2020

IPD Ann: Notice under Section 708A(5)(e) of the Corporations Act

IPD Ann: Appendix 2A

IPD Ann: ImpediMed Quarterly Results and Investor Conference Call

Register to track IPD and receive email alerts.

Similar Companies

AT1
COH
CSX
CYC
EMV
IBX
MX1
RSH
SOM